Table 1. Subject Characteristics During Baseline.
| Variables | Daily Trial | Nocturnal Trial | ||||||
|---|---|---|---|---|---|---|---|---|
| N | All (N=245) | 3 times (N=120) | 6 times (N=125) | N | All (N=87) | 3 times (N=42) | 6 times (N=45) | |
| Age (years) | 245 | 50.4 ± 13.9 | 52.0 ± 14.1 | 48.9 ± 13.6 | 87 | 52.8 ± 13.6 | 54.0 ± 12.9 | 51.7 ± 14.4 |
| Male | 245 | 151 (61.6%) | 73 (60.8%) | 78 (62.4%) | 87 | 57 (65.5%) | 28 (66.7%) | 29 (64.4%) |
| Race/Ethnicity | 245 | 87 | ||||||
| White/Caucasion, non-Hispanic | 89 (36.3%) | 46 (38.3%) | 43 (34.4%) | 48 (55.2%) | 21 (50.0%) | 27 (60.0%) | ||
| Black/African-American/African | 102 (41.6%) | 53 (44.2%) | 49 (39.2%) | 23 (26.4%) | 11 (26.2%) | 12 (26.7%) | ||
| Hispanic & non-Black | 69 (28.2%) | 31 (25.8%) | 38 (30.4%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Asian | 16 (6.5%) | 5 (4.2%) | 11 (8.8%) | 12 (13.8%) | 7 (16.7%) | 5 (11.1%) | ||
| Other/Unknown | 22 (9.0%) | 8 (6.7%) | 14 (11.2%) | 1 (1.1%) | 1 (2.4%) | 0 (0%) | ||
| ESRD vintage (years) | 245 | 87 | ||||||
| < 1 year (%) | 40 (16.3%) | 20 (16.7%) | 20 (16.0%) | 45 (51.7%) | 25 (59.5%) | 20 (44.4%) | ||
| 1 to < 2 years (%) | 32 (13.15) | 15 (12.5%) | 17 (13.6%) | 13 (14.9%) | 5 (11.9%) | 8 (17.8%) | ||
| 2 – 5 years (%) | 76 (31.0%) | 42 (35.0%) | 34 (27.2%) | 13 (14.9%) | 5 (11.9%) | 8 (17.8%) | ||
| > 5 years (%) | 97 (39.6%) | 43 (35.8%) | 54 (43.2%) | 16 (18.4%) | 7 (16.7%) | 9 (20.0%) | ||
| Diabetes | 245 | 100 (40.8%) | 50 (41.7%) | 50 (40.0%) | 87 | 37 (42.5%) | 18 (42.9%) | 19 (42.2%) |
| Congestive heart failure | 245 | 49 (20.0%) | 24 (20.0%) | 25 (20.0%) | 87 | 12 (13.8%) | 7 (16.7%) | 5 (11.1%) |
| Peripheral arterial disease | 245 | 25 (10.2%) | 10 (8.33%) | 15 (12.0%) | 87 | 15 (17.2%) | 7 (16.7%) | 8 (17.8%) |
| Stroke | 245 | 18 (7.3%) | 9 (7.5%) | 9 (7.2%) | 87 | 2 (2.3%) | 1 (2.4%) | 1 (2.2%) |
| Average weekly enPCR (g/kg/d) | 245 | 1.02 ± 0.25 | 1.03 ± 0.25 | 1.02 ± 0.25 | 84 | 0.99 ± 0.25 | 0.99 ± 0.23 | 0.98 ± 0.28 |
| PCR | 245 | 63.4 ± 20.0 | 63.4 ± 19.1 | 63.5 ± 20.9 | 84 | 63.6 ± 21.3 | 64.4 ± 22.4 | 62.8 ± 20.3 |
| Residual kidney function (ml/min) | 245 | 87 | ||||||
| = 0 | 162 (66.1%) | 72 (60.0%) | 90 (72%) | 24 (27.6%) | 11 (26.2%) | 13 (28.9%) | ||
| 0 - 1 | 37 (15.1%) | 19 (15.8%) | 18 (14.4%) | 16 (18.4%) | 9 (21.4%) | 7 (15.6%) | ||
| 1 - 3 | 42 (17.1%) | 27 (22.5%) | 15 (12.0%) | 28 (32.2%) | 14 (33.3%) | 14 (31.1%) | ||
| > 3 | 4 (1.6%) | 2 (1.7%) | 2 (1.6%) | 19 (21.8%) | 8 (19.0%) | 11 (24.4%) | ||
| Creatinine (mg/dL) | 245 | 10.54 ± 2.72 | 10.32 ± 2.45 | 10.76 ± 2.95 | 87 | 8.74 ± 2.99 | 8.89 ± 3.06 | 8.59 ± 2.94 |
| Phosphate (mg/dL) | 245 | 5.78 ± 1.64 | 5.64 ± 1.53 | 5.91 ± 1.73 | 87 | 5.80 ± 1.61 | 5.77 ± 1.65 | 5.82 ± 1.59 |
| Hemoglobin (g/dL) | 244 | 11.9 ± 1.3 | 12.0 ± 1.2 | 11.9 ± 1.3 | 87 | 11.8 ± 1.1 | 11.9 ± 1.1 | 11.6 ± 1.1 |
| PTH (pg/mL = ng/L) | 244 | 312 (69, 901) | 287 (52, 873) | 334 (89, 984) | 87 | 322 (77, 635) | 340 (112, 618) | 296 (77, 640) |
| Albumin (g/dL) | 245 | 3.94 ± 0.42 | 3.94 ± 0.46 | 3.94 ± 0.37 | 87 | 3.91 ± 0.49 | 3.92 ± 0.51 | 3.90 ± 0.48 |
| Calcium (mg/dL) | 245 | 9.01 ± 0.92 | 9.04 ± 0.96 | 8.99 ± 0.89 | 87 | 8.83 ± 0.80 | 8.96 ± 0.79 | 8.71 ± 0.80 |
| Bicarbonate (mmol/L) | 245 | 23.7 ± 3.7 | 23.7 ± 4.0 | 23.7 ± 3.4 | 87 | 22.9 ± 3.8 | 22.8 ± 3.6 | 22.9 ± 4.0 |
| BMI (kg/m2) | 245 | 27.6 ± 6.7 | 27.6 ± 6.8 | 27.5 ± 6.6 | 87 | 29.1 ± 7.9 | 28.4 ± 7.6 | 29.8 ± 8.3 |
| Phase angle (degrees) | 234 | 5.43 ± 1.51 | 5.21 ± 1.21 | 5.65 ± 1.74 | 78 | 5.51 ± 1.48 | 5.54 ± 1.48 | 5.49 ± 1.51 |
| Intra-cellular water (L)/Weight (kg) | 234 | 0.267 ± 0.062 | 0.261 ± 0.061 | 0.273 ± 0.062 | 78 | 0.268 ± 0.066 | 0.273 ± 0.065 | 0.264 ± 0.068 |
| Postdialysis Weight (kg) | 245 | 78.2 ± 20.5 | 78.7 ± 20.5 | 77.7 ± 20.7 | 87 | 85.5 ± 25.4 | 83.3 ± 23.8 | 87.6 ± 27.0 |
| Adiposity (kg) | 234 | 36.9±13.7 | 37.6±13.7 | 36.3±13.8 | 80 | 39.4±16.2 | 37.9±14.6 | 40.9±17.7 |
| TBW | 234 | 44.2 ± 9.9 | 43.9± 10.2 | 44.5 ± 9.7 | 78 | 47.3 ± 11.8 | 46.7 ± 11.4 | 47.9 ± 12.2 |
| ECW | 234 | 22.8 ± 4.5 | 22.9 ± 4.7 | 22.7 ± 4.4 | 78 | 24.2 ± 5.9 | 23.8 ± 5.6 | 24.6 ± 6.2 |
| ECW/ICW | 234 | 1.13 ± 0.31 | 1.16 ± 0.30 | 1.12 ± 0.32 | 78 | 1.12 ± 0.32 | 1.11 ± 0.32 | 1.13 ± 0.33 |
| Resistance (ohms) | 234 | 474 ± 95 | 488 ± 99 | 460 ± 89 | 80 | 468 ± 100 | 470 ± 90 | 467 ± 111 |
| Reactance (ohms) | 234 | 48.5 ± 13.3 | 48.2 ± 13.6 | 49.0 ± 14.1 | 78 | 48.1 ± 13.5 | 48.7 ± 13.3 | 47.5 ± 13.8 |
| Phase angle (degrees) | 234 | 5.43 ± 1.51 | 5.21 ± 1.21 | 5.65 ± 1.74 | 78 | 5.51 ± 1.48 | 5.54 ± 1.48 | 5.49 ± 1.51 |
| Vector length () | 234 | 284.9 ± 62.9 | 291.8 ± 64.2 | 278.0 ± 61.1 | 78 | 273.4 ± 61.7 | 274.5 ± 57.3 | 272.3 ± 66.3 |
Results are shown as mean ± standard deviation, median and 10th & 90th percentiles range, or frequency (%), as appropriate
There were no significant differences between the treatment groups in each of the separate trials (Daily and Nocturnal) at baseline.